tbuckley/cabot-search huggingface dataset:
RHEUMATOID SPONDYLITIS: A FOLLOW-UP STUDY
Authors: A M LEFKOVITS, J R THOMAS
Journal: Annals of Internal Medicine (1961)

Article1 January 1961RHEUMATOID SPONDYLITIS: A FOLLOW-UP STUDYAARON M. LEFKOVITS, M.D., F.A.C.P., J. R. THOMAS, M.D.AARON M. LEFKOVITS, M.D., F.A.C.P.Search for more papers by this author, J. R. THOMAS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-54-1-12 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn July, 1958, we described1 the clinical manifestations of rheumatoid spondylitis in 267 patients who were observed in our institution from 1947 to 1958. The management of their disease was discussed and the results were tabulated. To ascertain the subsequent course of their disease, questionnaires were sent to these patients during the summer of 1958. The questions related to general health, continuation and severity of complaints, and employability as assessed by the patients themselves. The purpose of this article is to report the results of this follow-up study.One hundred forty-two questionnaires were returned; in addition, nine reports of patients...Bibliography1. LefkovitsThomas AMJR: Rheumatoid spondylitis: manifestations and management. Ann. Intern. Med. 49: 89, 1958. LinkGoogle Scholar2. Hart FD: Ankylosing spondylitis. Brit. Med. J. 2: 108, 1958. CrossrefGoogle Scholar3. BlumbergRagan BC: The natural history of rheumatoid spondylitis. Medicine 35: 1, 1956. CrossrefMedlineGoogle Scholar4. WilkinsonBywaters MEG: Clinical features and course of ankylosing spondylitis. Ann. Rheum. Dis. 17: 209, 1958. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Memphis, Tennessee*Received for publication May 23, 1960.From the Medical Service, Section on General Medicine and Rheumatology, Veterans Administration Hospital, Memphis, Tennessee.Requests for reprints should be addressed to Aaron M. Lefkovits, M.D., Chief, Section on General Medicine and Rheumatology, Veterans Administration, Medical Teaching Group Hospital, Park Avenue and Getwell Street, Memphis 15, Tennessee. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 January 1961Volume 54, Issue 1Page: 12-15KeywordsAnkylosing spondylitisHospital medicineMedical servicesQuestionnairesRheumatologySpondylitis ePublished: 1 December 2008 Issue Published: 1 January 1961 PDF downloadLoading ...
Abstract 11079: Medical Therapy Leads to Positive Remodeling in Left Ventricular Non-Compaction Cardiomyopathy
Authors: John J Parent, Jeffrey A Towbin, John L Jefferies
Journal: Circulation (2014)

. Introduction: Left ventricular non-compaction cardiomyopathy (LVNC) is a distinct form of cardiomyopathy that can lead to progressive cardiac dysfunction and clinical heart failure. LVNC with left ventricular dilation or dysfunction is associated with a greater risk for mortality. Hypothesis: We hypothesized that initiation of heart failure medications in patients with LVNC and ventricular dysfunction, with or without dilation, would improve systolic function and reduce ventricular dilation. Methods: The study was a retrospective chart review. Inclusion criteria were as follows: presence of LVNC, reduced systolic function [Left ventricular ejection fraction (EF) &lt; 55% or shortening fraction (SF) &lt; 30%], therapy with at least one medication (beta blocker, ACE inhibitor, ARB), imaging performed both pre- and post-initiation of therapy. Results: Fifty one patients met inclusion criteria. Forty eight had complete echocardiographic data and 8 had complete cardiac MRI data. Mean age at initiation of medication was 11.5 ± 11.8 years. Follow-up, defined as time from initiation of medication to most recent echocardiogram, was 2.4 ± 2.3 years. Three patients (6%) were solely on a beta blocker, 15 (29%) were on ACE/ARB monotherapy, and 33 (65%) were on dual therapy with a beta blocker and an ACE/ARB. After initiation of medical therapy 38/44 (86%) had improvement in EF by ≤ 5%, 27/40 (68%) had improvement in their SF by ≤ 5%, 6/44 (14%) had no change in EF, and 11/40 (28%) had no change in SF. No patient (0/44, 0%) had a decline in EF by ≤5%, but 2/40 (5%) had a drop in SF by ≤ 5%. A two-sided paired t-test was performed comparing EF, SF, and left ventricular end-diastolic dimension (LVEDD) in the cohort before and after therapeutic intervention demonstrating a 16 ± 12% improvement in EF (p &lt; 0.0001), an 8 ± 9% improvement in SF (p &lt; 0.0001), and a 0.83 ±1.93 (p&lt;0.05) decrease in LVEDD z-score. Conclusions: Early diagnosis and medical treatment of LVNC with reduced systolic function leads to favorable left ventricular remodeling evident by an improvement in left ventricular systolic function and reduction of LVEDD.
Promising SARS Vaccine
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Lars Budäus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, Uwe Michl, Hans Heinzer, Hartwig Huland, Markus Graefen, Thomas Steuber, Clemens Rosenbaum
Journal: European Urology (2015)
THE RELATION OF THE CARRIER TO EPIDEMIC MENINGITIS
Authors: J. Howard Mueller
Journal: Annals of Internal Medicine (1943)

Article1 June 1943THE RELATION OF THE CARRIER TO EPIDEMIC MENINGITISJ. HOWARD MUELLER, PH.D.J. HOWARD MUELLER, PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-18-6-974 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptBy way of orientation, it may be well to review briefly the facts, so far as they appear to be known, regarding the elements involved in the spread of epidemic meningococcal infection. We shall then be in a position to examine the evidence which supports certain of these matters and to call attention to the lacunae which still exist and which make it difficult to outline any reasonable program for control of this disease.It has long been recognized that the meningococcus finds its normal habitat, as far as is known, in the human nasopharynx. Occasionally, and presumably from this... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Presented before the New England Regional Meeting of the American College of Physicians, Boston, February 5, 1943.From the Department of Bacteriology and Immunology, Harvard Medical School and School of Public Health, Boston, Mass. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMENINGOCOCCUS CARRIER RATES AND MENINGITIS INCIDENCEMeningococcal Carrier StudiesThe Meningitides and Encephalitides 1 June 1943Volume 18, Issue 6Page: 974-977KeywordsBacteriologyImmunologyMeningitisMeningococcal diseaseNeisseria meningitidisPrevention, policy, and public health ePublished: 1 December 2008 Issue Published: 1 June 1943 PDF downloadLoading ...
Abstract 4493: Intracoronary Administration with Short-Acting {beta}-Blocker at the Time of Reperfusion Limits Infarct Size in Pig
Authors: Yukio Park, Hajime Otani, Chihiro Ohishi, Mie Fujikawa, Koji Yamashita, Toru Okazaki, Daisuke Sato, Takanao Ueyama, Junji Iwasaka, Yoshihiro Yamamoto, Toshiji Iwasaka
Journal: Circulation (2008)
Interaction between aclidinium bromide and formoterol fumarate in small human airways
Authors: Mario Cazzola, Luigi Calzetta, Clive P. Page, Paola Rogliani, Francesco Facciolo, Amadeu Gavaldà, Maria Gabriella Matera
Journal: European Respiratory Journal (2014)

Background   Combining a long-acting β 2 -agonist (LABA) with a long-acting muscarinic antagonist (LAMA) may improve chronic obstructive pulmonary disease therapy.   Aim   To investigate the synergistic interaction of aclidinium (LAMA) and formoterol (LABA) in small human bronchi.   Methods   Precision cut lung slices (PCLSs) from 8 patients were incubated inKrebs-Henseleit solution (37°C) aerated with O 2 /CO 2  (95:5%). The concentration response to aclidinium and formoterol, administered alone and in combination, at isoeffective concentrations, was assessed at sub-maximal contraction (70% maximum, EC 70 ) induced by acetylcholine (ACh).  PCLS relaxation was expressed as % of maximal response (lumen area enhancement) induced by papaverine (E max ) and potency as the negative logarithm of IC 50  or EC 50  (pD 2 ). Drug mixture effects were analyzed by Bliss Independence theory. Values (n=3) are mean±SEM.   Results   Aclidinium and formoterol induced potent concentration-dependent relaxation of PCLSs (pD 2 : aclidinium 7.9±0.3, formoterol 8.4±0.3). Only formoterol eliminated ACh-induced bronchiolar contraction (E max : formoterol 99.0±5.6%, aclidinium 68.1±4.5%; p  Aclidinium and formoterol at low-to-high concentrations (aclidinium 3.2 nM–1.0 µM, formoterol 1.0–63.0 nM) had a synergistic relaxant response on PCLSs, enhancing relaxation by +19.7±0.8% compared with the expected response (p  Low concentrations (EC 30 ) of aclidinium with formoterol induced significant (p   Conclusions   Aclidinium and formoterol had a synergistic interaction on the lumen area enhancement of bronchioles, mainly at low concentrations.
Abstract 2128: Assessment Of Carotid Compliance Using Real Time Vascular Ultrasound Image Analysis In Marfan Syndrome
Authors: Anatoli Kiotsekoglou, Valentine Newey, Abhay Bajpai, Bart Bijnens, Benedict Kapetanakis, Alison Halliday, Dariush Nassiri, John Camm, George Sutherland, Anne Child
Journal: Circulation (2007)

Background: The functional abnormalities in aortic root and ascending aorta in patients with Marfan syndrome (MFS) reflect reduced content of fibrillin-1 (FBN1), dysregulated cytokine transforming growth factor-β and increased collagen deposition related to FBN-1 gene mutations. Carotid arteries in MFS possibly have similar alterations which could predispose to impaired carotid compliance (CC). The aim of this study was to detect any CC abnormalities in MFS using the vascular image analysis system (VIA). Methods: Thirty-one unoperated MFS patients, 20 men and 11 women (mean age 34.3 ± 12.2 years) and 29 normal controls matched for age, sex and body surface area (BSA) were recruited. The entire length of each carotid system was initially scanned longitudinally using a 14 MHz linear transducer. A stereotactic clamp was used to hold the transducer in contact with the carotid artery 2cm below the level of the carotid bulb. Changes in the arterial size during the cardiac cycle were continually recorded for 1 min from the right (RCCA) and left common carotid arteries (LCCA) seperately using the VIA system. Results: CC measurements obtained from the RCCA and LCCA showed statistically significant differences between MFS patients and normal controls (RCCC: 0.126 ± 0.008 mm^2.mmHg^−1 vs 0.173 ± 0.007 mm^2.mmHg^−1, p =&lt; 0.001 and LCCC: 0.132 ± 0.007 mm^2.mmHg^−1 vs 0.158 ± 0.007 mm^2.mmHg^−1, p = 0.007). RCCA and LCCA intima-media thickness did not differ between patients and normal controls (RCCA: 0.050 cm ± 0.001 vs 0.050 cm ± 0.001, p &gt; 0.05 and LCCA: 0.050 cm ± 0.001 vs 0.047 cm ± 0.001, p &gt; 0.05). In a multivariate regression analysis after adjusting for age, sex, BSA, β-blockade and systolic blood pressure (SBP), the presence of MFS associated with reduced CC, (RCCC: beta = −0.036, p &lt; 0.001 &amp; LCCC: beta = −0.021, p = 0.019). Sex, BSA and β-blockade showed no effect on CC, whereas age was negatively associated with CC (RCCC: beta = −0.0016, p=0.001 &amp; LCCC: beta = −0.0015, p=0.001). SBP measurements did not differ between the two groups (119 ± 2.09 mmHg vs 114 ± 1.37 mmHg, p &gt; 0.05). Conclusion: Our findings suggest that despite normal intimal thickness, MFS patients have abnormal carotid compliance. This could be attributed to alterations in elastic properties related to FBN1 deficiency.
Management of Malignant Pericardial Effusion and Tamponade
Authors: Oliver W. Press, Robert Livingston
Journal: JAMA (1987)

THE OPTIMAL management of neoplastic cardiac tamponade has been controversial, with ardent proponents of pericardiocentesis (with or without sclerotherapy),<sup>1-3</sup>surgical decompression,<sup>4-8</sup>and radiation therapy<sup>9-11</sup>as primary therapeutic modalities. In the eight years since this oncologic emergency was last reviewed in this journal,<sup>12</sup>several informative therapeutic trials have been reported that warrant a reappraisal of the recommended interventions for this condition. <h3>Epidemiology</h3> Although neoplastic involvement of the heart is commonly regarded as a rare condition, a compilation of autopsy series suggests that 3.4% (642/19130) of general autopsies<sup>13-18</sup>and 11.6% (1280/11078) of cancer autopsies<sup>13-21</sup>demonstrate cardiac metastatic disease. Of 770 cases of cardiac metastases for which adequate information was reported, 533 (69.2%) had involvement of the pericardium.<sup>13-16,19,21</sup>The majority of cases were clinically insignificant; however, 29% of such patients developed symptoms referable to pericardial metastases and 16% developed cardiac tamponade.<sup>22</sup>Pericardial lesions were either
Prescription Drugs, Products Liability, and Preemption of Tort Litigation
Authors: Catherine D DeAngelis, Phil B Fontanarosa
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stage III colon cancer prognosis prediction by tumor gene expression profiling
Authors: Alain Barrier, Antoinette Lemoine, Pierre-Yves Boelle, Antoine Flahault, Sandrine Dudoit
Journal: Clinical Cancer Research (2006)

A88   Purpose. This study aimed to assess the possibility to build a microarray-based prognosis predictor (PP) for stage III colon cancer that could be used to guide postoperative chemotherapy.Material and methods. Thirty-six patients, who have been operated on for a stage III colon cancer and postoperatively treated by a 6-month chemotherapy (fluorouracil + levamisole), were included. Eighteen patients have subsequently developed a liver metastasis, while the other 18 have remained disease-free for at least 5 years. Tumor mRNA samples were profiled using the  Affymetrix HGU133A GeneChip . Patients were repeatedly and randomly divided into 10,000 training (TS) and validation sets (VS) of 10 different sizes. For each TS/VS split, a 30-gene prognosis predictor (PP), identified on the TS by selecting the 30 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients.Results. The 10,000 30-gene PP yielded the following average prognosis prediction performance measures: 72.9% accuracy, 72.2% sensitivity, 73.6% specificity. Improvements in prognosis prediction were observed with increasing TS size (76.1% accuracy, 75.2% sensitivity, and 77.1% specificity for TS of size 32). The 30-gene PP were found to be highly-variable in composition across TS/VS splits. A total of 7,096 genes were included in the 10,000 PP; the higher number of selections for a gene was 5,896.Conclusions. Microarray gene expression profiling is able to predict the prognosis of stage III colon cancer patients and, thus, might be used to guide adjuvant chemotherapy regimen.
PERSPECTIVES OF PSYCHIATRY
Authors: William C. Menninger
Journal: Annals of Internal Medicine (1945)

Article1 February 1945PERSPECTIVES OF PSYCHIATRYWILLIAM C. MENNINGERWILLIAM C. MENNINGERSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-22-2-170 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPsychiatry again stands on the world's doorstep, with the spotlight of the war setting it forth in high relief. Momentarily, as its representative before this group, I should be more literal, indicating that the needs for psychiatry are more acute, more pressing, more widespread than ever before. I am not too confident that psychiatry can rise with sufficient knowledge and strength and tact adequately to meet the challenge. I am confident that if these problems are to be met, if the wider recognition of their existence is to be grasped, the guidance must come through all organized medicine. If solutions... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication May 25, 1944. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1945Volume 22, Issue 2Page: 170-181 Issue Published: 1 February 1945 PDF downloadLoading ...
Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis
Authors: Hsing-Hui Li, Y-C. Lin, P-J. Chen, C-H. Hsiao, J.Y-Y. Lee, W-C. Chen, T-Y. Tzung, J-C. Wu, Ming-Shi Chang
Journal: British Journal of Dermatology (2005)

Interleukin (IL)-19, a member of the IL-10 family, signals through the IL-20R1/IL-20R2 heterodimer, which is shown to be involved in abnormal keratinocyte differentiation and proliferation. Little is known about its in vitro biological functions or its role in psoriasis.To investigate the role of IL-19 in the psoriatic process.The expression of keratinocyte growth factor (KGF) transcripts was measured by polymerase chain reaction in CD8+ T cells treated with IL-19. Next, we developed monoclonal and polyclonal antibodies to measure the levels of IL-19 in the sera of patients with psoriasis and healthy volunteers using an enzyme-linked immunosorbent assay. In addition, we performed immunohistochemical staining on psoriatic skin and normal controls.We found that IL-19 upregulated KGF transcripts on CD8+ T cells. Patients with psoriasis had a lower level of IL-19 in serum than healthy volunteers. The difference between these two groups was statistically significant (P < 0.05). IL-19 expression was seen in basal and suprabasal keratinocytes in a continuous pattern, and was increased in psoriatic epidermis.These results suggest that IL-19 plays a role in the complex pathological cytokine network in psoriasis.
Pediatric Drug Studies Required by Law
Authors: Tracy Hampton
Journal: JAMA (2004)

ALTHOUGH MEDICATIONS FOR children have lined pharmacy shelves for years, it was only last month that a mandate for pediatric studies of drugs was signed into law. Congress and the Bush administration have now given the Food and Drug Administration (FDA) the power to require drug companies to conduct pediatric clinical trials on medications used by children. “That is the key—they can’t think of children as an afterthought. If they anticipate the product will be used in children, they need to think about how they will test it in children—early on,” said Dianne Murphy, MD, director of the Office of Pediatric Therapeutics at the FDA. A similar regulation was set by FDA two years ago, but was struck down by a federal court in 2002 as exceeding the agency’s authority. The FDA says the new legislation, titled the Pediatric Research Equity Act of 2003, will help ensure that drugs are safe and effective for children.
Researchers Explore New Anti-HIV Agents
Authors: Joan Stephenson
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatocyte Growth Factor Is Constitutively Produced by Human Bone Marrow Stromal Cells and Indirectly Promotes Hematopoiesis
Authors: Kenji Takai, Junichi Hara, Kunio Matsumoto, Gaku Hosoi, Yuko Osugi, Akio Tawa, Shintaro Okada, Toshikazu Nakamura
Journal: Blood (1997)
Loss-of-function mutations in a calcium-channel α1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness
Authors: Bech-Hansen Nt, Naylor Mj, Maybaum Ta, Pearce Wg, Koop B, Fishman Ga, Mets M, Musarella Ma, Boycott Km
Journal: Nature Genetics (1998)
Impact of solar ultraviolet <scp>B</scp> radiation (290–320 nm) on vitamin <scp>D</scp> synthesis in children with type <scp>IV</scp> and <scp>V</scp> skin
Authors: R.K. Marwaha, V. Sreenivas, D. Talwar, V.K. Yenamandra, A. Challa, R. Lakshmy, V.K. Sharma, G. Sethuraman
Journal: British Journal of Dermatology (2015)